Acumen pharmaceuticals to deliver late-breaking presentation at 17th annual clinical trials on alzheimer's disease (ctad) conference

- presentation to focus on use of validated ptau217 assay in participant screening process for phase 2 altitude-ad study of sabirnetug for early alzheimer's disease

ABOS Ratings Summary

ABOS Quant Ranking